Alimentiv

For over 30 years, our purpose has been clear: transforming the lives of people living with GI disease through pioneering research and innovative clinical trial development. At ECCO 2026, we’ll unveil a refreshed brand that embodies who we are and the mission that drives us — advancing GI science to make a real difference for patients. loom.ly/xp0LTec #Alimentiv #GI #ClinicalTrials #CRO #IBD #ECCO2026 #brandreveal #brandrefresh

Don't miss Renee Ambrose, Site Network Director, this week at the Crohn's & Colitis Congress. Renee is connecting with GI clinical trial investigators in Las Vegas, Nevada and exploring opportunities to partner with us by joining Alimentiv’s global network of 5,000+ sites across 60+ countries. Learn more about how we support GI clinical research worldwide. 👉 loom.ly/_Qi076E #CCCongress26 #Alimentiv #ClinicalTrials #GI

The VERDICT study team is excited to announce that 95% of the participants have completed the study! We thank the patients and caregivers, investigators, and site study teams for their support in achieving this exciting milestone and look forward to sharing results from this study soon. The VERDICT study aims to determine the optimal treatment target for assessing disease activity and response to therapy in ulcerative colitis, which is a research priority for disease management. Results will inform clinical practice, regulatory endpoints, and targets for drug development. VERDICT is a collaborative study between Alimentiv and Takeda and a testament to the dedication of both organizations to improve the lives of patients living with IBD.

𝗘𝗻𝗱-𝘁𝗼-𝗘𝗻𝗱 𝗚𝗜 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀—𝗧𝗮𝗶𝗹𝗼𝗿𝗲𝗱 𝗳𝗼𝗿 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 Gastroenterology clinical trials come with unique challenges, requiring a partner with deep GI expertise and a proven track record. At #Alimentiv, that’s exactly what you get – the most specialized GI CRO with above industry average patient recruitment metrics and seamless execution. With our risk-based framework and proactive approach, we bring the most efficient recruitment strategies, enhance study quality, and increased efficiency—helping sponsors accelerate time-to-market. 𝗪𝗵𝗮𝘁 𝘀𝗲𝘁𝘀 𝘂𝘀 𝗮𝗽𝗮𝗿𝘁? ✅ Unmatched GI Specialization ✅ Streamlined Efficiency ✅ Data-Driven Excellence ✅ Best-in-Class Technology Suite ✅ Collaborative Partnership 🔗 Explore our full range of services: loom.ly/7fQRgPk #ClinicalTrials #GI #Alimentiv

At Alimentiv, we connect sponsors with leading AI solutions shaping the future of GI research – like with our partnerships with DovaVision™ and PathwaysGI that seek to advance endoscopy and disease assessment with greater precision and consistency. Curious about how these innovations could impact your next trial? Book a meeting now: loom.ly/d0Zy9QQ #Alimentiv #GIResearch #AIInHealthCare

𝗧𝗵𝗲 𝗙𝗗𝗔’𝘀 𝗻𝗲𝘄 𝗱𝗿𝗮𝗳𝘁 𝗴𝘂𝗶𝗱𝗮𝗻𝗰𝗲 𝗼𝗻 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗺𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗮 𝘁𝗼𝗼𝗹 𝗳𝗼𝗿 𝘀𝘁𝘂𝗱𝘆 𝗱𝗲𝘀𝗶𝗴𝗻 𝗮𝗻𝗱 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘄𝗵𝗶𝗰𝗵 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃 𝗰𝗮𝗻 𝗮𝗽𝗽𝗹𝘆 𝘁𝗼 𝗚𝗜 𝘀𝘁𝘂𝗱𝗶𝗲𝘀. The use of Bayesian statistics in trial design and analysis provides a powerful option for improving the efficiency of clinical trials. #Alimentiv recognizes the remarkable possibilities offered by Bayesian approaches, especially in the areas of ulcerative colitis and Crohn’s disease where it is critical to maximize the potential of our trials in a field where sample sizes can be limited and a wealth of control data are available. Alimentiv has been at the forefront of the GI field in proposing #Bayesian solutions to scientific questions. Our statisticians have many years of expertise using Bayesian thinking and techniques to trial design and analysis; from post-hoc usage for treatment comparisons to external controls, to advocating for hybrid-control designs in #GI at international conferences, to proposing Bayesian designs for dose-finding in early phase trials. With the release of this draft guidance, adoption of Bayesian methodologies into regulatory clinical trials will accelerate across the industry, and Alimentiv will be there to continue leading this discussion with experience and expertise. 🔗 Read the FDA draft guidance: loom.ly/CAzFuTc

🌍 𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗿𝘂𝗹𝘆 𝗵𝗼𝗹𝗶𝘀𝘁𝗶𝗰, 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁‐𝗰𝗲𝗻𝘁𝗲𝗿𝗲𝗱 𝗜𝗕𝗗 𝗰𝗮𝗿𝗲 𝗹𝗼𝗼𝗸 𝗹𝗶𝗸𝗲? Dr. Marjolijn Duijvestein, gastroenterologist at the Radboud UMC (Nijmegen, Netherlands) and former Alimentiv IBD Research Fellow offers a compelling look at the future of gastroenterology—from greener clinical practices to smart technologies that could transform how we monitor and treat IBD. Dr. Duijvestein shares insights on: • Reducing the environmental footprint of GI care • The importance of personalized treatment strategies • How collaboration across research, clinics, and industry can accelerate progress 👉 Read the full interview: loom.ly/nXwVKVM #Alimentiv #ClinicalTrials #ClinicalTrialInvestigators

Did you know that Alimentiv has supported >70% of IBD compounds currently in development? Our deep understanding of gastrointestinal science and clinical trial experience is unmatched. We're proud to play a pivotal role in bringing innovative therapies to market and improving the lives of countless patients. Discover how #Alimentiv is shaping the future of #GI medicine: loom.ly/yqvQWJ8 #Alimentiv #ClinicalTrials #IBD

At Alimentiv, we're proud that our exclusive collaboration with IBUS (International Bowel Ultrasound Group) enables us both to continue advancing intestinal ultrasound (IUS) as an additional imaging modality in GI clinical trials. Since 2023, we have been delivering high-quality IUS central reading services for clinical trials in IBD—bringing together our expertise in clinical research with IBUS’s leadership in IUS training and research. Learn more 👉 loom.ly/peaDdL4 #Alimentiv #ClinicalTrials #GI #IBD #IntestinalUltrasound #IBUS

In the complex field of clinical research, partnering with a specialized CRO is key. Alimentiv has over 30 years of GI-related experience and offers end-to-end clinical trial services. Our unmatched expertise spans all trial phases, starting from clinical trial management to imaging and precision medicine. We partner with you to deliver innovative solutions for your studies. Learn why we are the trusted partner for leading pharmaceutical & biotech companies: loom.ly/WuT5f2I #Alimentiv #ClinicalTrials #GI

𝗦𝘁𝗮𝗿𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝘄 𝘆𝗲𝗮𝗿 𝘄𝗶𝘁𝗵 𝗽𝘂𝗿𝗽𝗼𝘀𝗲? 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿 𝗷𝗼𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃 𝘁𝗲𝗮𝗺. If you’re looking for meaningful work, an inclusive culture, and a company that prioritizes employee well‑being, this could be your next step. Start 2026 with work that matters: loom.ly/E754aNw #Alimentiv #Hiring #Careers #JobOpportunities

As we close out 2025, 🎆 we reflect on an extraordinary year of achievements made possible by the unwavering support of our customers, partners, and collaborators. Your trust and collaboration have driven our mission forward, and we couldn't be more grateful. A special thank you to our incredible teams who work tirelessly to advance GI clinical research—your dedication fuels our success. Here’s to making an even greater impact together in 2026! Thank you for being an integral part of our journey. Happy New Year! ✨️ #Alimentiv #HappyNewYear

How is Alimentiv leveraging #AI solutions to advance EoE histopathology? Alimentiv’s innovative digital image analysis tool helps pathologists score patient biopsies and improve the histopathological assessment of eosinophilic esophagitis (EoE) samples in #ClinicalTrials by making it faster, efficient, and more accurate. Dive deeper to discover how: loom.ly/KHzYICA #Alimentiv #PrecisionMedicine #MedicalResearch #ClinicalTrials #EoE #DigitalPathology

A bonus holiday wish from our team to yours — wishing you a happy and bright end to the year! #Alimentiv #HappyHolidays 𝘔𝘶𝘴𝘪𝘤 𝘣𝘺 𝘙𝘈

🚀 𝟱𝟬,𝟬𝟬𝟬 𝗦𝘁𝗿𝗼𝗻𝗴 𝗮𝗻𝗱 𝗥𝗶𝘀𝗶𝗻𝗴 🚀 We’ve officially crossed 50,000 followers and we’re still growing! Thank you for being here and for fueling this incredible community. 🌍 Every single follow represents curiosity, commitment, and momentum in our shared mission to advance GI research and improve patient lives. Here’s to the next 50,000 — more breakthroughs, more collaboration, and more impact. Let’s keep it going. 🔥 #TeamAlimentiv

🎄✨ Happy holidays from all of us at Alimentiv! This season is a time to pause, reflect, and celebrate the moments that matter most. We’re grateful for the community that surrounds us and the shared impact we’ve made together. Wishing you joy, peace, and meaningful connections with family and friends. 💙 #Alimentiv #HappyHolidays 𝘔𝘶𝘴𝘪𝘤 𝘣𝘺 𝘖𝘭𝘪𝘷𝘦𝘳 𝘔𝘢𝘴𝘴𝘢

Looking for expert #GI clinical trial support? Look no further than Alimentiv, the industry-leading GI CRO ✨ We're committed to improving trial outcomes and accelerating drug development timelines for global GI studies. 𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗱𝗼 𝗶𝘁? 🚀 50% faster patient recruitment than industry standards. 🌍 A network of 5,000+ GI sites across 60+ countries—and growing. 📊 Exclusive GI imaging data accelerating site selection and startup. 🔬 Industry-leading provider of imaging solutions for IBD and GI-related diseases 👥 GI medical leadership on all projects 🥼 Global leaders for #GI central reading expertise If you're ready to start your GI trials with a partner that has deep GI expertise with unmatched efficiency, let's discuss today! loom.ly/XANQJx8 #Alimentiv #ClinicalTrials #ClinicalResearch

In case you missed our first announcement, we're pleased to share that 25% of patients have been enrolled in the VECTORS study!  The study team would like to express gratitude to the patients, investigators and site study teams for the support in achieving this exciting milestone.   VECTORS is a unique study in #CrohnsDisease (CD) research provide insights on the optimal treatment algorithm to achieve a target of transmural healing in patients living with Crohn’s disease. VECTORS will also provide data on the utility of intestinal ultrasound as a non-invasive modality in Crohn’s disease clinical trials and clinical practice.    VECTORS is a collaborative study between Alimentiv and Takeda and a testament to the dedication of both organizations to improve the lives of patients living with IBD.     Learn more: bit.ly/3zkz1tX  #Alimentiv #IBD #Ultrasound #MedicalResearch #ClinicalTrials

Celiac disease drug development is changing, but promising therapies may never reach the finish line without standardized trial methodologies. Our latest article explores how collaboration, standardization, and innovation are transforming celiac clinical research, and why it matters for sponsors and patients. 👉 loom.ly/dF30X1M #CeliacDisease #ClinicalTrials #GIResearch #MedicalResearch #TrialDesign

✨ 𝗪𝗲'𝗿𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗜𝗕𝗗 𝗧𝗼𝗱𝗮𝘆 & 𝗧𝗼𝗺𝗼𝗿𝗿𝗼𝘄 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺! Our team is on site connecting with GI clinical trial investigators, sharing insights, and advancing conversations that shape the future of #IBD research. It’s inspiring to see the global GI community come together to push innovation forward — and we’re honored to be part of it. #IBDTodayTomorrow2025 #Alimentiv #ClinicalTrials #GI